PCN27 BUDGET IMPACT ANALYSIS OF MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA

To determine the budget impact of incorporating midostaurin to induction and consolidation therapies in combination with chemotherapy agents and as monotherapy during the maintenance phase in FLT3 mutation-positive acute myeloid leukemia (AML) compared with chemotherapy with no midostaurin from the social security perspective in Argentina. A budget impact model provided by Novartis and developed by Purple Squirrel Economics was adapted for a...